The world first 2nd-generation COVID-19 vaccine approved for emergency use

The world first 2nd-generation COVID-19 vaccine approved for emergency use

The world first 2nd-generation COVID-19 vaccine approved for emergency use. 

On December 27, the UAE Ministry of Health and Prevention approved the emergency use of the second-generation recombinant protein COVID-19 vaccine of Sinopharm China Biotech.

This is also the world’s first second-generation COVID-19 vaccine approved for emergency use.

The COVID-19 vaccine has broad-spectrum protection against a variety of mutant strains.

The UAE has carried out relevant research on the vaccine, and it will be used as a booster for people who have been vaccinated with two doses of China’s new biological COVID-19 inactivated vaccine.

The recombinant protein COVID-19 vaccine is developed by the scientific research team of the Chinese Academy of Biological Sciences and has independent intellectual property rights.

On the basis of the first-generation recombinant protein COVID-19 vaccine, the R&D team conducted a comprehensive analysis and evaluation of the immune escape ability and evolutionary laws of various mutant strains, and newly designed and developed the second-generation recombinant protein COVID-19 vaccine.

Pre-clinical effectiveness studies and preliminary human trials have shown that the second-generation vaccine has broad-spectrum protection potential against a variety of variant strains and is currently the only second-generation vaccine approved for emergency use.

Please scan the QR code, fill in the information carefully, and join the mRNA vaccine technology exchange WeChat group after the review is passed!

At present, the COVID-19 vaccine has been vaccinated with nearly 2,000 subjects in the UAE.

Preliminary research results show that the vaccine is safe and tolerable, and can stimulate the human body to produce high levels of neutralizing antibodies against the prototype strain and the main variant strain.

It fully embodies the advantages and characteristics of the recombinant protein vaccine technology route in vaccine research and development.

▲UAE Ministry of Health and Prevention

UAE Health Health and Prevention Department confirmed that the emergency use of the new vaccine crown in full compliance with laws and regulations and review procedures.

This is part of the hard work of the Ministry of Health and the health authorities to strengthen the prevention of the COVID-19 pneumonia pandemic by community members.

This move reflects the UAE’s strategy to ensure the health and safety of members of the community and its continued efforts to fight the epidemic through all possible means.

Sinopharm Sinopharm is the only company in the world that has developed four COVID-19 vaccines on three technical routes. At present, China’s biological COVID-19 vaccine has been registered and marketed in 10 countries around the world, and 112 countries, regions and international organizations have approved emergency use or market access.

China Bio will continue to work with partners to jointly build a community of human health and contribute China’s strength.

Knowledge:

The recombinant protein COVID-19 vaccine is based on the natural structural features of the receptor binding domain (RBD) of the COVID-19 spike protein (S protein).

It uses structural biology and computational biology to independently design and develop, and uses genetic engineering technology to construct engineered cell lines and recombinant expression Antigen protein, clear target, strong pertinence.

After immunization, it can induce the body to produce targeted neutralizing antibodies, thereby blocking the combination of the virus and the recipient cells and exerting a protective effect.

The recombinant protein vaccine has a mature technical route and is suitable for large-scale production.

Live virus and other infectious materials are not involved in the whole preparation process, and it does not need to be carried out in a high-grade biosafety environment.

The production speed is faster, and it is easy to store and distribute.

The world first 2nd-generation COVID-19 vaccine approved for emergency use

(source:internet, reference only)

Disclaimer of medicaltrend.org